NIDCD awards research grant to Mobius Therapeutics

Mobius Therapeutics, LLC ™ has been awarded a research grant from the National Institute on Deafness and other Communication Disorders (NIDCD) to study its investigational procedure, selective Photodynamic Myringotomy (PDM).

PDM is a procedure where the tympanic membrane (ear drum) is treated with a specially stained anti-scarring agent. The stained tissue is then exposed to a specially tuned laser, designed to be absorbed only at the site of the stain. The procedure treats ear infections by opening the membrane to ventilate and drain the ear. The anti-scarring agent slows the healing process which allows the ear to stay ventilated, while eliminating the need for pressure equalization tubes and the associated surgery.

"The potential of PDM is enormous," said Ed Timm, President of Mobius Therapeutics. "Otitis media is the single most common reason for a child to visit the doctor. In the USA alone, bilateral myringotomy with tubes accounts for an estimated 2,000,000 surgeries each year on children under the age of 16. The ability to replace an anesthetized hospital surgical procedure with a single, painless office procedure would be welcomed by both children and parents."

"This grant will allow Mobius to achieve measurable milestones," Timm continued. "The rapid issuance of broad patent protection compelled us to accelerate the development of PDM. We are grateful to NIDCD and corporate supporters that have made this development possible."

Source:

Mobius Therapeutics, LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how antimicrobial exposure affects Parkinson’s disease risk